|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 249.80 DKK | +1.15% |
|
+7.90% | -23.20% |
| 10:20pm | India warns drugmakers against direct or surrogate weight-loss drug and obesity ads | RE |
| 06:51pm | Novo Nordisk, WHO Sign, Expand Partnerships for Cardio-Renal-Metabolic Conditions | MT |
| Capitalization | 1,110B 172B 148B 134B 128B 234B 15,847B 240B 1,585B 632B 7,577B 645B 631B 27,292B | P/E ratio 2026 * |
11.6x | P/E ratio 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise value | 1,215B 188B 163B 147B 140B 256B 17,356B 263B 1,736B 692B 8,299B 706B 691B 29,891B | EV / Sales 2026 * |
4.26x | EV / Sales 2027 * | 4.01x |
| Free-Float |
70.25% | Yield 2026 * |
4.33% | Yield 2027 * | 4.54% |
Last Transcript: Novo Nordisk A/S
| 1 day | +1.15% | ||
| 1 week | +7.90% | ||
| Current month | +5.00% | ||
| 1 month | -20.69% | ||
| 3 months | -19.18% | ||
| 6 months | -28.86% | ||
| Current year | -23.20% |
| 1 week | 244.3 |  | 255.85 |
| 1 month | 224.25 | | 314.85 |
| Current year | 224.25 | | 409.95 |
| 1 year | 224.25 | | 573.3 |
| 3 years | 224.25 | | 1,033.2 |
| 5 years | 210.08 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 07/08/2025 | |
| Director of Finance/CFO | 55 | 15/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 56 | 07/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 61 | 23/03/2017 |
| Director/Board Member | 51 | 22/03/2018 | |
| Director/Board Member | 61 | 24/03/2022 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.07% | 21.31% | 1,387 M€ | |
| +0.41% | 10.45% | 4 M€ | |
| -1.55% | 5.4% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.15% | +7.90% | -54.53% | -50.02% | 171B | |
| -0.15% | -0.78% | +20.50% | +217.39% | 895B | |
| -0.30% | -1.52% | +44.90% | +60.27% | 587B | |
| +0.30% | -2.64% | +5.09% | +52.08% | 401B | |
| -1.55% | -7.15% | +7.35% | +25.17% | 345B | |
| -0.62% | -4.08% | +19.59% | +62.48% | 300B | |
| -1.16% | -3.00% | +22.31% | +35.39% | 306B | |
| -0.75% | -3.02% | +22.03% | +7.91% | 289B | |
| +0.59% | +0.17% | +15.36% | +65.73% | 202B | |
| -1.72% | -1.24% | +24.56% | +83.65% | 184B | |
| Average | -0.36% | -1.14% | +12.72% | +56.00% | 368.14B | |
| Weighted average by Cap. | -0.41% | -1.51% | +18.11% | +84.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 285B 44.21B 38.2B 34.49B 32.98B 60.12B 4,077B 61.81B 408B 162B 1,949B 166B 162B 7,021B | 301B 46.65B 40.31B 36.39B 34.81B 63.44B 4,302B 65.23B 430B 171B 2,057B 175B 171B 7,409B |
| Net income | 93.57B 14.49B 12.52B 11.3B 10.81B 19.71B 1,336B 20.26B 134B 53.26B 639B 54.37B 53.23B 2,301B | 95.81B 14.84B 12.82B 11.57B 11.07B 20.18B 1,368B 20.75B 137B 54.54B 654B 55.67B 54.5B 2,356B |
| Net Debt | 106B 16.37B 14.14B 12.77B 12.21B 22.26B 1,509B 22.88B 151B 60.16B 722B 61.41B 60.12B 2,599B | 99.82B 15.46B 13.36B 12.06B 11.53B 21.02B 1,425B 21.61B 143B 56.82B 682B 58B 56.78B 2,455B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/03/26 | 249.80 kr | +1.15% | 4,248,086 |
| 10/03/26 | 246.95 kr | -2.97% | 5,391,158 |
| 09/03/26 | 254.50 kr | +2.66% | 7,069,910 |
| 06/03/26 | 247.90 kr | -0.30% | 6,430,038 |
| 05/03/26 | 248.65 kr | +1.30% | 6,130,778 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition